Modimelanotide
As of the edition of 20 October 2026, Modimelanotide is a protein: stopped in 2014; acts on MC1R and MC3R.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2014
- Kind
- Protein
- Registered trials
- 5, 2 stopped early
- Disease areas
- Pregnancy and women's health; Urinary and reproductive; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
4 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product4 company-target rows are on route A because of Modimelanotide.
See the 4 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 5 | 3 | 0 | 2 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Action Pharma A/S | Lead sponsor of trials | 2008 to now |
| AbbVie | Lead sponsor of trials | 2013 to now |